ARS Pharmaceuticals Inc [SPRY] stock is trading at $17.56, down -1.90%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SPRY shares have gain 3.60% over the last week, with a monthly amount glided 21.94%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ARS Pharmaceuticals Inc [NASDAQ: SPRY] stock has seen the most recent analyst activity on March 07, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $30. Previously, Oppenheimer started tracking the stock with Outperform rating on February 10, 2025, and set its price target to $40. On August 20, 2024, Cantor Fitzgerald initiated with a Overweight rating. Raymond James upgraded its rating to a Strong Buy and increased its price target to $22 on August 13, 2024. Leerink Partners reiterated its recommendation of a Outperform and raised its price target to $20 on August 12, 2024. Raymond James started tracking with a Outperform rating for this stock on July 25, 2024, and assigned it a price target of $18. In a note dated March 05, 2024, Leerink Partners upgraded an Outperform rating on this stock and boosted its target price from $6 to $18.
ARS Pharmaceuticals Inc [SPRY] stock has fluctuated between $8.91 and $18.90 over the past year. Currently, Wall Street analysts expect the stock to reach $23.33 within the next 12 months. ARS Pharmaceuticals Inc [NASDAQ: SPRY] shares were valued at $17.56 at the most recent close of the market. An investor can expect a potential return of 32.86% based on the average SPRY price forecast.
Analyzing the SPRY fundamentals
Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.28%, Pretax Profit Margin comes in at -0.16%, and Net Profit Margin reading is -0.16%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.07 and Total Capital is -0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.17 points at the first support level, and at 16.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.98, and for the 2nd resistance point, it is at 18.39.
Ratios To Look Out For
For context, ARS Pharmaceuticals Inc’s Current Ratio is 11.00. Further, the Quick Ratio stands at 10.74, while the Cash Ratio is 1.44. Considering the valuation of this stock, the price to sales ratio is 17.76, the price to book ratio is 7.53.
Transactions by insiders
Recent insider trading involved Karas Eric, Chief Commercial Officer, that happened on Jul 01 ’25 when 15000.0 shares were sold. 10% Owner, Flynn James E completed a deal on Jun 27 ’25 to sell 0.74 million shares. Meanwhile, Officer ERIC KARAS bought 15000.0 shares on Jul 01 ’25.
